Septerna doses first participants in Phase 1 trial of SEP-631

Septerna (SEPN) announced the dosing of the first participants in its Phase 1 clinical trial of SEP-631, a selective oral small molecule Mas-related G protein-coupled receptor X2 negative allosteric modulator being developed for the treatment of chronic spontaneous urticaria and other mast cell-driven diseases. The Phase 1 single-ascending dose and multiple-ascending dose clinical trial will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of SEP-631 in healthy adult volunteers.